TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05641480
Drug: Donepezil hydrochloride tablets or carpalatine bitartrate tablets
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ① Donepezil hydrochloride tablets 5 mg, once a day, one tablet each time, before going to bed. The treatment period is 6 months.~② Carpalatine heavy tartrate tablets 1.5mg, 1 tablet/time 2 weeks before treatment, twice a day, breakfast and dinner with food, swallow. If there is no obvious adverse reaction after 2 weeks, the dosage can be increased to 2 tablets/time, twice a day. The treatment period is 6 months.
Study: NCT05259189
Drug: NBL-012 Injection
Normalized name: NBL-015
DrugBank: NBL-015 (DB18183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single subcutaneous injection
Study: NCT06249802
Drug: Nebivolol
Normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-month intake of medication
Study: NCT05696665
Drug: Saffron and Chamomile
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given saffron and chamomile in capsule formulation twice daily
Study: NCT05696665
Drug: Crocin and Apigenin
Normalized name: crocin
DrugBank: Apigenin (DB07352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ingredients of saffron(Crocin) and Chamomile(Apigenin) will be given in capsule formultaion once daily
Study: NCT05064436
Drug: 11C-BMS-986196
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04900116
Drug: Bupivacaine HCl 0.5 % in 20 ML Injection
Normalized name: BUPivacaine HCl 0.5 % in 20 ML Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this group, US guided PENG block will be performed with 20 ml 0.5% bupivacaine using a 22 gauge 10 mm block needle.
Study: NCT04900116
Drug: Bupivacaine HCl 0.25 % in 20 ML Injection
Normalized name: BUPivacaine HCl 0.25 % in 20 ML Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this group, US guided PENG block will be performed with 20 ml 0.25% bupivacaine using a 22 gauge 10 mm block needle.
Study: NCT04900116
Drug: Bupivacaine HCl 0.125 % in 20 ML Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this group, US guided PENG block will be performed with 20 ml 0.125% bupivacaine using a 22 gauge 10 mm block needle.
Study: NCT00000658
Drug: Bleomycin sulfate
Normalized name: Bleomycin Sulfate
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000658
Drug: Vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000658
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000658
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000658
Drug: Sargramostim
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000658
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04823247
Drug: Tildrakizumab
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As provided in real world clinical practice.
Study: NCT03891849
Drug: Octreotide Injection
Normalized name: octreotide Injection
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients admitted in intensive care unit after variceal hemorrhage treated with norepinephrine perfusion will received an additional octreotide perfusion during one hour.
Study: NCT04423861
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive nitazoxanide 600 mg BID for 7 days.
Study: NCT06027723
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine delivered through a vape
Study: NCT05305404
Drug: Dexamethasone Oral
Normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.5mg oral dexamethasone to be administered once at 11:00PM
Study: NCT04899219
Drug: ACT-1014-6470 40 mg
Normalized name: ACT-541468
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-1014-6470 will be available as soft gelatin capsules for oral administration formulated at a dose strength of 20 mg.
Study: NCT05119101
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: we will give mg sulphate and then measure intracranial pressure at different intervals by measuring Optic nerve sheath diameter (ONSD).
Study: NCT05414058
Drug: Apo-Methylphenidate ER
Normalized name: methylphenidate Extended Release Suspension
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For inpatients, the study medication will be administered by unit nurses, alongside their other medications. For outpatients, the study medication will be dispensed to the participant by the research assistant during their weekly visit. Patients will continue their regular medications as per standard of care.
Study: NCT05957380
Drug: DA-2803
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants are administered one tablet per day for 48 weeks
Study: NCT05216757
Drug: Iguratimod
Normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: iguratimod, 25mg bid po.
Study: NCT04575948
Drug: Moringa Oleifera
Normalized name: Moringa Oleifera
DrugBank: Moringa oleifera leaf (DB14362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non toxic Moringa extract with antibacterial and antiplaque effect will be used
Study: NCT04575948
Drug: Chlorhexidine mouthwash
Normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial 0.12% chlorhexidine digluconate mouthwash twice daily (each morning and before bedtime during the 21-day study period) after intake of food. The patient will be asked to use 15 ml of mouthwash swish it for 60 sec. then expectorate.
Study: NCT06129851
Drug: Relugolix
Normalized name: Relugolix
DrugBank: Relugolix (DB11853)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06006026
Drug: Ropivacaine Hydrochloride 10 MG/ML [Naropin]
Normalized name: ropivacaine hydrochloride 10 MG/ML [Naropin]
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: According to the specified dosage, dilute 1% ropivacaine to 0.2% and inject 1/2 of the total amount on each side.
Study: NCT00034502
Drug: ALIMTA
Normalized name: Alimta
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00034502
Drug: irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04633278
Drug: CMP-001
Normalized name: Cmp-001 component cpg-a oligodeoxynucleotide tlr9 agonist
DrugBank: Vidutolimod (DB17500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive CMP-001 10mg weekly for 2 doses after which CMP-001 will be administered every 3 weeks. The first dose of CMP-001 may be administered subcutaneously (SC) or Intratumorally (IT) at the discretion of Investigator. All subsequent doses will be injected intratumorally every 3 weeks (Q3W).
Study: NCT04633278
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg IV is administered Q3W.
Study: NCT00348062
Drug: Bimatoprost
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05866315
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administer remimazolam
Study: NCT05866315
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administer desflurane
Study: NCT05991401
Drug: DA-8010 5mg
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[Period 1\] DA-8010 5mg \[Period 2\] DA-8010 5mg, Clarithromycin 500mg \[Period 3\] DA-8010 5mg, Rifampicin 600mg
Study: NCT05991401
Drug: Rifampicin 600mg
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: \[Period 3\] DA-8010 5mg, Rifampicin 600mg
Study: NCT04449250
Drug: Dexmethylphenidate
Normalized name: Dexmethylphenidate
DrugBank: Dexmethylphenidate (DB06701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be randomized to one of two sequences. Subjects will be dosed with 25 mg dose of CTx-1301 during each sequence. Subjects will serve as their own control.
Study: NCT05327296
Drug: Isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled isoflurane administered by Sedaconda ACD-S
Study: NCT05327296
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion of propofol
Study: NCT05603975
Drug: Esketamine 0.1mg/kg intravenous injection
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Esketamine was administered intravenously at 0.1mg per kilogram of body weight 1min before the dressing change.
Study: NCT05710237
Drug: Psilocybin 25 mg
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with either risperidone 1 mg or place. It will also be administered in conjunction with supportive therapy.
Study: NCT05710237
Drug: Risperidone 1 MG
Normalized name: risperidone 1 MG
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The risperidone is encapsulated using a cellulose capsule and contains 1 mg of risperidone. The risperidone will be administered once during the trial in combination with either psilocybin 25 mg or placebo. It will also be administered with supportive therapy.
Study: NCT05934409
Drug: Nicotinic Acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Only during A1. 150mg every half hour for 6 hours. A total dose of 1800mg will be ingested.
Study: NCT06392009
Drug: Radiprodil
Normalized name: Radiprodil
DrugBank: Radiprodil (DB12260)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
Study: NCT04768881
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose and formulation: 80 mg (4 tablets of 20 mg)
Study: NCT04768881
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose and formulation: 400 mg (25 milligrams per milliliter \[mg/mL\]) Solution
Study: NCT04663282
Drug: Insulin Degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin Degludec injected subcutaneously once daily. Treat-to-target dose titration during the trial
Study: NCT06176235
Drug: Teriflunomide
Normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Teriflunomide 7 mg orally once daily for 24 weeks. Dose adjustments were made throughout the study based on individual platelet counts.
Study: NCT06176235
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 40 mg orally once daily for four consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 14).
Study: NCT05115630
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by IV
Study: NCT05115630
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV
Study: NCT05115630
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by IV
Study: NCT05115630
Drug: Fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by IV
Study: NCT05115630
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by IV
Study: NCT05115630
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV
Study: NCT05115630
Drug: Total Body Irradiation One Dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV
Study: NCT04928508
Drug: OK-1
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: OK-1 orally in the form of 50 mg capsules. Four dose levels will be evaluated:~5.4mg/kg 7.0mg/kg 9.0mg/kg 12mg/kg
Study: NCT05770375
Drug: MDMA 40mg
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA 40mg
Study: NCT05770375
Drug: MDMA 80mg
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA 80mg
Study: NCT05770375
Drug: MDMA 120mg
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA 120mg
Study: NCT06315634
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 micrograms intrathecal dexmedetomidine
Study: NCT06315634
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 milligrams intrathecal midazolam
Study: NCT06315634
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12.5 milligrams 0.5% intrathecal hyperbaric bupivacaine
Study: NCT05711459
Drug: Bicyclol tablets
Normalized name: alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
DrugBank: Bicyclol (DB16014)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take Bicyclol tablets for the treatment of liver injury.
Study: NCT05074459
Drug: Eptinezumab Mammalian Cell Line
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Concentrate for solution for IV infusion
Study: NCT05074459
Drug: Eptinezumab Yeast Cell Line
Normalized name: Eptinezumab
DrugBank: Yeast (DB11017)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Concentrate for solution for IV infusion
Study: NCT06722118
Drug: Dexamethasone IV
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV-DXM 4mg/ml, injectable solution. Dosage of 0.25 mg/kg (maximum 5 mg per dose), prepared in a syringe of 5 to 10 ml and administered intravenously to the patient over 10 minutes every 6 hours. The treatment duration ranges from 6 hours (minimum of two doses: H0, H6) to 18 hours (maximum of four doses: H0, H6, H12, H18).
Study: NCT04999540
Drug: Tucidinostat
Normalized name: tucidinostat
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 30 mg, administered orally twice per week (BIW)
Study: NCT06723548
Drug: Telitacicept
Normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with MG who fulfill the inclusion criteria will receive Telitacicept 240mg weekly as an adjunct to their medication. Upon reaching MMS, significant symptom improvement, or a QMG score reduction of at least 6 points, Telitacicept is reduced to biweekly doses. Pyridostigmine and NSISTs are tapered based on patient response. Following this, Prednisone is tapered, starting with rapid reduction early and slowing later. If a patient on 60mg Prednisone daily achieves treatment goals within 6-8 weeks of Telitacicept initiation, the tapering sequence is 60mg every other day for 4 weeks, then 30mg daily for 2-4 weeks, and so on, until reaching 5mg daily or 10mg every other day. At this point, Telitacicept may be reduced to 160mg biweekly.
Study: NCT04999540
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
Study: NCT05064137
Drug: Monomeric self - assembling peptide P11-4
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monomeric self - assembling peptide P11-4 ( Curodont Repair ) is a remineralizing agent applied on tooth surface after treating it with 3% sodium hypochlorite for 20 seconds then etching it with 37% phosphoric acid for 20 seconds followed by rinsing then dryness.
Study: NCT05064137
Drug: fluoride varnish (5% sodium fluoride)
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluoride varnish (5% sodium fluoride) ( Voco-profluorid ) is a remineralizing agent applied on tooth surface then area is allowed to become wet (either by gentle rinsing or natural salivary flow) to ensure setting of VOCO Profluorid Varnish.
Study: NCT06724250
Drug: Botulinum Toxin A (Botox )
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin is injected into the pelvic floor muscles to reduce muscle overactivity and improve coordination, aiming to relieve symptoms of dyssynergic defecation.
Study: NCT06722196
Drug: topical amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amiodarone soaked patch placed on the left atrial roof at the end of surgery
Study: NCT05248152
Drug: Pregabalin 150mg
Normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive pregabalin 150 mg in the hour before surgery
Study: NCT05185869
Drug: SHR6390
Normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR6390, Oral Administration
Study: NCT05185869
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-albumin, Intravenous Injection
Study: NCT05185869
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine, Intravenous Injection
Study: NCT06725004
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection Oxytocin 10 mg intramuscular as trigger for ovulation induction
Study: NCT06725004
Drug: Human Chorionic Gonadotropin
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection Human Chorionic Gonadotropin 5000 IU intramuscular as trigger for ovulation induction
Study: NCT05196295
Drug: Hydrogen
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants take either 1 (n=5), 3 (n=5) or 6 (n=5) capsules every day for one month.
Study: NCT05788484
Drug: CDX-585
Normalized name: CDX
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDX-585 is administered by infusion every 2 weeks
Study: NCT05338346
Drug: ATG-018
Normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation Phase:~For both dose escalation groups, subjects will receive a single dose of ATG-018 monotherapy on Cycle 1 Day 1 (C1D1) for single dose PK samples' collection. From the morning dose on Cycle 1 Day 2, twice daily dosing (except Dose Level 1: 5 mg QD) will be initiated. Subject(s) will receive intermittent dosing in a 3 days on/4 days off schedule in 21-day cycles until disease progression or unacceptable toxicity.~Dose Expansion Phase :~Dose Expansion Phase will begin at the defined MTD/RP2D for solid tumors and hematological malignancies groups, to further evaluate the safety, tolerability, and PDx profile of ATG-018. Subjects with solid tumors and hematological malignancies will be enrolled.
Study: NCT04854928
Drug: LTX-109 gel, 3%
DrugBank: LTX-109 (DB12711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Single dose of LTX-109 gel will be applied topically to both nostrils by a qualified health professional. A large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
Study: NCT05999227
Drug: 68Ga-FAPI-04
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A fibroblast activation protein (FAP) -targeted PET imaging agent
Study: NCT05999227
Drug: 18F-FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A general glucose metabolism imaging agent
Study: NCT06220929
Drug: Mecobalamin
Normalized name: Mecobalamin
DrugBank: Mecobalamin (DB03614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The drug Mecobalamin in the intervention group was divided into intravenous and oral formulations, with the intravenous formulation being used for the first 14 days of the experiment and the oral formulation for the second 14 days.
Study: NCT06220929
Drug: Ceftriaxone Sodium
Normalized name: Ceftriaxone Sodium
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone sodium all intravenous formulations
Study: NCT06220929
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The saline used in the control group was the same as the saline used in the experimental group to dispense the drug
Study: NCT00002330
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05267613
Drug: Nexium 20mg
Normalized name: Nexium 20mg Powder for Injection
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.